Naylor Stuart 4

What Happened

• Stuart Naylor, Chief Scientific Officer, Ophthalmology at MeiraGTx Holdings plc, received a grant of 70,000 restricted share units (RSUs) on 2026-06-25. The reported acquisition price is $0.00 per unit — this is an equity award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-25; Filing date: 2026-06-29 (filed within required reporting window).
• Award amount: 70,000 RSUs; reported price: $0.00 (derivative award).
• Shares owned after transaction: not specified in the filing excerpt.
• Footnotes: F1 — each RSU converts into one ordinary share upon vesting. F2 — vesting schedule: 50% on the 2nd anniversary of the grant date, 25% on the 3rd anniversary, and 25% on the 4th anniversary.
• No indication in the filing of tax withholding, 10b5-1 plan, or immediate sale of shares.

Context

• This is a routine equity compensation grant to an executive and does not reflect an open-market buy or sell. RSUs have no immediate cash value until they vest and convert into shares; vesting timing determines when the insider will actually receive tradable stock.